Loading...
Market
Story
FDA Authorizes Updated Novavax COVID-19 Vaccine for Ages 12 and Older
Aug 30, 2024, 06:43 PM
The U.S. Food and Drug Administration (FDA) has granted emergency use authorization for an updated Novavax COVID-19 vaccine. This vaccine is authorized for individuals aged 12 years and older. The updated vaccine is designed to more closely target currently circulating variants, aiming to provide better protection against serious outcomes of COVID-19, such as hospitalization and death. This authorization offers an alternative to mRNA vaccines, expanding the options available for COVID-19 vaccination.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 1 million • 25%
1-5 million • 25%
5-10 million • 25%
More than 10 million • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-5 million doses • 25%
5.1-10 million doses • 25%
10.1-15 million doses • 25%
15.1+ million doses • 25%
Less than 10 million • 25%
10-20 million • 25%
21-30 million • 25%
More than 30 million • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50,000 • 25%
50,000 to 99,999 • 25%
100,000 to 150,000 • 25%
More than 150,000 • 25%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Less than 1 million • 25%
1 million to 3 million • 25%
3 million to 5 million • 25%
More than 5 million • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%